Seminars in Radiation Oncology
Volume 13, Issue 1 , Pages 3-12 , January 2003

Clinical promise tempered by reality in the delivery of combined chemoradiation for common solid tumors

References 

  1. Vokes EE, Weichselbaum RR, Lippman SM, et al.  Head and neck cancer. N Engl J Med. 1993;328:184–194
  2. Forastiere A, Koch W, Trotti A, et al.  Medical progress—Head and neck cancer. N Engl J Med. 2001;345:1890–1900
  3. Merlano M, Benasso M, Corvo R, et al.  Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst. 1996;88:583–589
  4. Wendt TG, Grabenbauer GG, Rodel CM, et al.  Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol. 1998;16:1318–1324
  5. Brizel DM, Albers ME, Fisher SR, et al.  Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:1798–1804
  6. Calais G, Alfonsi M, Bardet E, et al.  Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081–2086
  7. Adelstein DJ, Lavertu P, Saxton JP, et al.  Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer. 2000;88:876–883
  8. Jeremic B, Shibamoto Y, Milicic B, et al.  Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol. 2000;18:1458–1464
  9. Corvo R, Benasso M, Sanguineti G, et al.  Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck—Results from a phase III randomized trial. Cancer. 2001;92:2856–2867
  10. Staar S, Rudat V, Stuetzer H, et al.  Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50:1161–1171
  11. Bourhis J, Lapeyre M, Tortochaux J, et al.  Preliminary results of the GORTEC 96-01 randomized trial comparing very accelerated radiotherapy versus concomitant radio-chemotherapy for locally inoperable HNSCC. Proc Am Soc Clin Oncol. 2002;21:227A; (abstr)
  12. Browman GP, Hodson DI, Mackenzie RJ, et al.  Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis. Head & Neck. 2001;23:579–589
  13. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol. 1996;14:838–847
  14. Munro AJ. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer. 1995;71:83–91
  15. Pignon JP, Bourhis J, Domenge C, et al.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949–955
  16. Stell PM, Rawson NS. Adjuvant chemotherapy in head and neck cancer. Br J Cancer. 1990;61:779–787
  17. Ang KK. Altered fractionation trials in head and neck cancer. Semin Radiat Oncol. 1998;8:230–236
  18. Mendenhall WM, Parsons JT. Altered fractionation in radiation therapy for squamous-cell carcinoma of the head and neck. Cancer Invest. 1998;16:594–603
  19. Peters LJ. Accelerated fractionation using the concomitant boost: A contribution of radiobiology to radiotherapy. Br J Radiol. 1992;24(suppl):200–203
  20. Fu KK, Pajak TF, Trotti A, et al.  A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48:7–16
  21. Horiot JC, Le Fur R, N'Guyen T, et al.  Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol. 1992;25:231–241
  22. Anonymous . Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group N Engl J Med. 1991;324:1685–1690
  23. Forastiere AA, Berkey BA, Maor M, et al.  Phase III trial to preserve the larynx: Induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone, Intergroup Trial R91-11. Proc Am Soc Clin Oncol. 2001;20:2A; (abstr)
  24. Lefebvre JL, Chevalier D, Luboinski B, et al.  Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J. Natl. Cancer Inst. 1996;88:890–899
  25. Eisbruch A, Marsh LH, Martel MK, et al.  Comprehensive irradiation of head and neck cancer using conformal multisegmental fields: Assessment of target coverage and noninvolved tissue sparing. Int J Radiat Oncol Biol Phys. 1998;41:559–568
  26. Harari PM, Huang SM. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol. 2001;11:281–289
  27. Landis SH, Murray T, Bolden S, et al.  Cancer statistics, 1999. Ca: a Cancer Journal for Clinicians. 1999;49:8–31
  28. Perez CA, Bauer M, Edelstein S, et al.  Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys. 1986;12:539–547
  29. Dillman RO, Herndon J, Seagren SL, et al.  Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996;88:1210–1215
  30. Sause WT, Scott C, Taylor S, et al.  Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995;87:198–205
  31. Brodin O, Nou E, Mercke C, et al.  Comparison of induction chemotherapy before radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung. The Swedish Lung Cancer Study Group. Eur J Cancer. 1996;32A:1893–1900
  32. Anonymous . Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group BMJ. 1995;311:899–909
  33. Buccheri G, Ferrigno D. Therapeutic options for regionally advanced non-small cell lung cancer. Lung Cancer. 1996;14:281–300
  34. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer. 1995;76:593–601
  35. Rowell NP, O'Rourke NP. Synchronous chemoradiotherapy for non-small cell lung cancer [protocol]. Cochrane Database of Systematic Reviews. 2002;(Issue 3): Cochrane Lung Cancer Group
  36. Schaake-Koning C, van den Bogaert W, Dalesio O, et al.  Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326:524–530
  37. Trovo MG, Minatel E, Franchin G, et al.  Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1992;24:11–15
  38. Furuse K, Fukuoka M, Takada T. Phase III study of concurrent vs. sequential thoracic radiotherapy (TRT) in combination with mitomycin, vindesine, and cisplatin in unresectable stage II non-small cell lung cancer: Five-year median follow-up results. Proc Am Soc Clin Oncol. 1999;18:458a
  39. Curran WJ, Scott C, Langer C. Phase III comparison of sequential vs concurrent chemoradiation for pts with unresected stage III non-small cell lung cancer (NSCLC): Initial report of radiation therapy oncologyy gropu (RTOG) 9410. Proc Am Soc Clin Oncol. 2000;19:484A; (abstr)
  40. Lee JS, Scott C, Komaki R, et al.  Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation therapy oncology group protocol 91-06. J Clin Oncol. 1996;14:1055–1064
  41. Jeremic B, Shibamoto Y, Acimovic L, et al.  Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol. 1995;13:452–458
  42. Jeremic B, Shibamoto Y, Acimovic L, et al.  Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol. 1996;14:1065–1070
  43. Movsas B, Scott C, Curran WJ, et al.  A quality-adjusted time without symptoms or toxicity (QTWIST) analysis of radiation therapy oncology group (RTOG) 94-10. Proc Am Soc Clin Oncol. 2001;20:313A; (abstr)
  44. Antonadouk D, Synodinou M, Boufi M, et al.  Ethyol reduces acutee toxicity during radiochemotherapy in patients with localized advanced stage non small cell lung cancer. Proc Am Soc Clin Oncol. 2000;19:501A; (abstr)
  45. Choy H, Akerley W, De Vore RF. Concurrent paclitaxel, carboplatin, and radiation therapy for locally advanced non-small cell lung cancer. Semin Oncol. 1999;26:36–43 (suppl)
  46. Komaki R, Lee JS, Kaplan B, et al.  Randomized phase III study of chemoradiation + Ethyol in patients with inoperable stage II-III non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2001;20:A1298; (abstr)
  47. Werner-Wasik M, Axelrod R, Friedland DP, et al.  Preliminary report on reduction of esophagitis by Ethyol in patients with non-small-cell lung cancer treated with chemoradiotherapy. Clin Lung Cancer. 2001;2:284–289
  48. Werner-Wasik M, Scott C, Curran WJ, et al.  Correlation between acute esophagitis and late pneumonitis in patients (pts) with locally advanced non-small cell lung cancer (LANSCL) receiving concurrent thoracic radiotherapy (RT) and chemotherapy: A multivariate analysis of the Radiation Therapy Oncology Group (RTOG) database. Proc Am Soc Clin Oncol. 2002;21:299a
  49. Curran WJ, Scott C, Bonomi P, et al.  Initial report of locally advanced multimoality protocol (LAMP): ACR 427: A randomized 3-arm phase II study of paclitaxel, carboplatin, and thoracic radiation for patients with stage III non-small cell lung cancer. Proc Am Soc Clin Oncol. 2001;20:312A; (abstr)
  50. Scagliotti GV, DeMarinis F, Rinaldi L. Phase III randomizd trial comparing three platinum-based doublets in advanced non small cell lung cancer. Proc Am Soc Clin Oncol. 2001;20:308A; (abstr)
  51. Van Meerbeeck J, Smit E, Lianes P. An EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol. 2001;20:308A; (abstr)
  52. Rodriguez J, Pawel J, Pluzanska A. A muilticenter randomized phase III study of docetaxel + cisplatin and docetaxel + carboplatin vs. vinorelbine + cisplatin in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol. 2001;20:314A; (abstr)
  53. Schiller JH, Harrington D, Belani CP, et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98

☆ Address reprint requests to Paul M. Harari, MD, Department of Human Oncology, UW-Madison Medical School, 600 Highland Avenue, K4/332, Madison, WI 53792.

PII: S1053-4296(03)50003-0

doi: 10.1053/srao.2003.50001

Seminars in Radiation Oncology
Volume 13, Issue 1 , Pages 3-12 , January 2003

Article Tools